Danila Valmori

11.6k total citations · 1 hit paper
139 papers, 9.5k citations indexed

About

Danila Valmori is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Danila Valmori has authored 139 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Immunology, 69 papers in Molecular Biology and 21 papers in Oncology. Recurrent topics in Danila Valmori's work include Immunotherapy and Immune Responses (109 papers), T-cell and B-cell Immunology (86 papers) and vaccines and immunoinformatics approaches (59 papers). Danila Valmori is often cited by papers focused on Immunotherapy and Immune Responses (109 papers), T-cell and B-cell Immunology (86 papers) and vaccines and immunoinformatics approaches (59 papers). Danila Valmori collaborates with scholars based in Switzerland, United States and France. Danila Valmori's co-authors include Pedro Romero, Maha Ayyoub, Jean‐Charles Cerottini, Danielle Líénard, Donata Rimoldi, Daniel E. Speiser, Mikäel J. Pittet, Philippe Guillaume, Vincenzo Cerundolo and Valérie Dutoit and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Danila Valmori

139 papers receiving 9.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth

1999 1.1k citations Danila Valmori, Pedro Romero et al. profile →

Peers

Countries citing papers authored by Danila Valmori

Since Specialization

Citations

This map shows the geographic impact of Danila Valmori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danila Valmori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danila Valmori more than expected).

Fields of papers citing papers by Danila Valmori

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danila Valmori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danila Valmori. The network helps show where Danila Valmori may publish in the future.

Co-authorship network of co-authors of Danila Valmori

This figure shows the co-authorship network connecting the top 25 collaborators of Danila Valmori. A scholar is included among the top collaborators of Danila Valmori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danila Valmori. Danila Valmori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessment of MAGE-A Expression in Resected Non–Small Cell Lung Cancer in Relation to Clinicopathologic Features and Mutational Status of EGFR and KRAS 2014 ·Cancer Immunology Research ·Maha Ayyoub, Lorenzo Memeo, Emilio Álvarez‐Fernández, Cristina Colarossi, (unknown), (unknown), Daniela Martinetti, Danila Valmori	21
2	Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer 2014 ·OncoImmunology ·Danila Valmori, Maha Ayyoub	1
3	CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity 2012 ·Cancer Research ·(unknown), Caroline Raffin, Isabelle Raimbaud, Pascale Pignon, Junko Matsuzaki, Kunle Odunsi, Danila Valmori, Maha Ayyoub	125
4	Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-γ–Secreting Cells as They Differentiate into Effector T Cells In Vivo 2012 ·Cancer Research ·Ahmed Hamaï, Pascale Pignon, Isabelle Raimbaud, (unknown), Hélène Senellart, Sandrine Hiret, Jean-Yves Douillard, Jaafar Bennouna, Maha Ayyoub, Danila Valmori	31
5	Human RORγt ⁺ T _H 17 cells preferentially differentiate from naive FOXP3 ⁺ Treg in the presence of lineage-specific polarizing factors 2010 ·Proceedings of the National Academy of Sciences ·Danila Valmori, Caroline Raffin, Isabelle Raimbaud, Maha Ayyoub	133
6	Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer 2009 ·Cancer Research ·Feng Qian, Jeannine Villella, Paul K. Wallace, Paulette Mhawech‐Fauceglia, Joseph D. Tario, Chris Andrews, Junko Matsuzaki, Danila Valmori, Maha Ayyoub, Peter J. Frederick, Amy Beck, Jianqun Liao, Richard Cheney, Kirsten B. Moysich, Shashikant Lele, Protul Shrikant, Lloyd J. Old, Kunle Odunsi	118
7	Human memory FOXP3+ Treg secrete IL-17 ex-vivo and constitutively express the TH17 lineage specific transcription factor ROR{gamma}t 2009 ·The Journal of Immunology ·Maha Ayyoub, Florence Deknuydt, Isabelle Raimbaud, Christelle Dousset, Lucie Leveque, Gilles Bioley, Danila Valmori	110
8	HLA Class I–Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine 2008 ·Clinical Cancer Research ·Gilles Bioley, Philippe Guillaume, Immanuel F. Luescher, (unknown), Bo Dupont, Nina Bhardwaj, Gregory Mears, Lloyd J. Old, Danila Valmori, Maha Ayyoub	15
9	SSX antigens as cancer vaccines 2005 ·Danila Valmori	2
10	CD4+ T Cell Responses to SSX-4 in Melanoma Patients 2005 ·The Journal of Immunology ·Maha Ayyoub, Andrea Merlo, Charles S. Hesdorffer, Donata Rimoldi, Daniel E. Speiser, Jean-Charles Cerottini, Yao-Tseng Chen, Lloyd J. Old, Stefan Stevanović, Danila Valmori	16
11	Identification of an SSX-2 Epitope Presented by Dendritic Cells to Circulating Autologous CD4+ T Cells 2004 ·The Journal of Immunology ·Maha Ayyoub, Charles S. Hesdorffer, (unknown), Stefan Stevanović, Gerd Ritter, Yao‐Tseng Chen, Lloyd J. Old, Daniel E. Speiser, Jean‐Charles Cerottini, Danila Valmori	16
12	Final Antigenic Melan-A Peptides Produced Directly by the Proteasomes Are Preferentially Selected for Presentation by HLA-A0201 in Melanoma Cells 2004 ·The Journal of Immunology* ·Laurence Chapatte, Catherine Servis, Danila Valmori, Odile Burlet‐Schiltz, (unknown), Bernard Monsarrat, Pedro Romero, (unknown)	18
13	Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs 2003 ·The Journal of Immunology ·Sacha Gnjatic, Djordje Atanackovic, Mitsutoshi Matsuo, Elke Jäger, (unknown), Danila Valmori, Yao-Tseng Chen, Gerd Ritter, Alexander Knuth, Lloyd J. Old	49
14	Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting 2002 ·Journal of Clinical Investigation ·Valérie Dutoit, Robert N. Taub, Kyriakos P. Papadopoulos, Susan Talbot, (unknown), (unknown), Sacha Gnjatic, Paul E. Harris, Brygida Bisikirska, Philippe Guillaume, Jean‐Charles Cerottini, Charles S. Hesdorffer, Lloyd J. Old, Danila Valmori	9
15	Positional Scanning-Synthetic Peptide Library-Based Analysis of Self- and Pathogen-Derived Peptide Cross-Reactivity with Tumor-Reactive Melan-A-Specific CTL 2002 ·The Journal of Immunology ·Verena Rubio‐Godoy, Valérie Dutoit, Yingdong Zhao, Richard Simon, Philippe Guillaume, Richard A. Houghten, Pedro Romero, Jean‐Charles Cerottini, Clemencia Pinilla, Danila Valmori	51
16	Vaccination with a Melan-A Peptide Selects an Oligoclonal T Cell Population with Increased Functional Avidity and Tumor Reactivity 2002 ·The Journal of Immunology ·Danila Valmori, Valérie Dutoit, Valérie Schnüriger, Anne‐Lise Quiquerez, Mikäel J. Pittet, Philippe Guillaume, Verena Rubio‐Godoy, Paul R. Walker, Donata Rimoldi, Danielle Líénard, Jean‐Charles Cerottini, Pedro Romero, Pierre‐Yves Dietrich	78
17	The Activatory Receptor 2B4 Is Expressed In Vivo by Human CD8+ Effector αβ T Cells 2001 ·The Journal of Immunology ·Daniel E. Speiser, Marco Colonna, Maha Ayyoub, Marina Cella, Mikäel J. Pittet, Pascal Batard, Danila Valmori, Philippe Guillaume, Danielle Líénard, Jean‐Charles Cerottini, Pedro Romero	74
18	Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue 2000 ·The Journal of Immunology ·Danila Valmori, Frédéric Lévy, Isabelle Miconnet, Paul Zajac, Giulio C. Spagnoli, Donata Rimoldi, Danielle Líénard, Vincenzo Cerundolo, Jean‐Charles Cerottini, Pedro Romero	64
19	Tetramer-Guided Analysis of TCR β-Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients 2000 ·The Journal of Immunology ·Danila Valmori, Valérie Dutoit, Danielle Líénard, Ferdy J. Lejeune, Daniel E. Speiser, Donata Rimoldi, Vincenzo Cerundolo, Pierre‐Yves Dietrich, Jean‐Charles Cerottini, Pedro Romero	78
20	Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma 2000 ·The Journal of Immunology ·Donata Rimoldi, Verena Rubio‐Godoy, Valérie Dutoit, Danielle Líénard, Suzanne Salvi, Philippe Guillaume, Daniel E. Speiser, Elisabeth Stockert, Giulio C. Spagnoli, Catherine Servis, Jean‐Charles Cerottini, Ferdy J. Lejeune, Pedro Romero, Danila Valmori	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact